{"success":true,"data":{"pressRelease":{"id":"170116","rtpr_id":"nPn1NKwkSa-20261015","ticker":"2137","exchange":"HKEX","all_tickers":["2137"],"title":"Brii Biosciences Unveils BRiSC™, an siRNA Therapeutics Discovery Platform","author":"PR Newswire","published_at":"2026-10-15T11:30:01.282Z","article_body":"Brii Biosciences Unveils BRiSC™, an siRNA Therapeutics Discovery Platform\nPR Newswire\n\nDURHAM, N.C. and BEIJING, Oct. 15, 2026\n\nProprietary BRiSC™ platform to advance the discovery and development of\nnext-generation dual-targeting siRNA medicines\n\nInitial focus on prevalent metabolic dysfunctions where complex disease\nbiology and overlapping comorbidities will benefit from coordinated modulation\nof multiple therapeutic targets\n\nDURHAM, N.C. and BEIJING, Oct. 15, 2026 /PRNewswire/ -- Brii Biosciences\nLimited (https://www.briibio.com/en/)  (\"Brii Bio\" or the \"Company\", stock\ncode: 2137.HK), a biotechnology company developing therapies to improve\npatient health and choice across diseases with high unmet medical need, today\nannounced the launch of BRiSC™ (Bispecific RNAiSilenCing), a proprietary\nsmall interfering ribonucleic acid (siRNA) therapeutics discovery platform to\nadvance the discovery and development of next-generation ribonucleic acid\n(RNA)-based therapies.\n\nBRiSC™ integrates a suite of four complementary technologies spanning\nsequence optimization, chemical modification, dual-targeting architectures,\nand targeted delivery approaches. Collectively, these complementary\ncapabilities are designed to enhance the selectivity, performance and\ntherapeutic reach of siRNA medicines, supporting the development of\ndifferentiated therapies for a broad range of diseases.\n\nThrough continued investment in its internal discovery organization,\nlaboratories in Beijing and Shanghai, and RNA technology capabilities, Brii\nBio has expanded its internal research and development capabilities across\ntarget discovery, translational science, and preclinical development. These\ncapabilities serve as the foundation for BRiSC™, which is already driving\nthe progression of multiple internal discovery programs.\n\nAs one of BRiSC™'s core capabilities, the dual-targeting architecture is\ndesigned to enable a single siRNA therapeutic to simultaneously silence two\ndistinct targets, addressing diseases driven by multiple biologic pathways,\nthrough a single treatment. Brii Bio is initially applying this approach to\nprevalent disease areas where complex biology and/or overlapping comorbidities\nmay potentially benefit from coordinated modulation of multiple therapeutic\ntargets.\n\n\"BRiSC™ reflects our commitment to building differentiated scientific\ncapabilities across multiple dimensions of siRNA therapeutic discovery and\ndevelopment,\" said Dr. Brian Johns, Chief Science Officer of Brii Bio. \"Our\ndual-targeting platform exemplifies this approach by combining innovative\nmolecular design with deep insights into disease biology to address conditions\ndriven by multiple unique pathways. Our goal is to develop differentiated RNA\ntherapeutics that can deliver broader and more meaningful benefits for\npatients\", he added.\n\nAbout Brii Bio\n\nBrii Biosciences Limited (\"Brii Bio\", stock code: 2137.HK) is a biotechnology\ncompany developing therapies to improve patient health by addressing diseases\nwith high unmet medical needs with limited treatment options. The Company is\nadvancing a broad pipeline of differentiated therapeutic candidates, including\ninternally discovered programs through its in-house RNA technology\ncapabilities such as its proprietary BRiSC™ siRNA discovery platform. The\nCompany is led by an experienced leadership team and has operations in China\nand the United States. For more information, visit www.briibio.com\n(https://www.briibio.com/) .\n\nView original\ncontent:https://www.prnewswire.com/news-releases/brii-biosciences-unveils-brisc-an-sirna-therapeutics-discovery-platform-302909942.html\n(https://www.prnewswire.com/news-releases/brii-biosciences-unveils-brisc-an-sirna-therapeutics-discovery-platform-302909942.html)\n\nSOURCE Brii Biosciences Limited\n\n\n\nMedia Inquiries: media@briibio.com; Investor Inquiries: ir@briibio.com; Partnering Inquiries: bd@briibio.com\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn1NKwkSa-20261015","title":"Brii Biosciences Unveils BRiSC™, an siRNA Therapeutics Discovery Platform","author":"PR Newswire","ticker":"2137","created":"2026-10-15T11:30:01.282Z","tickers":["2137"],"exchange":"HKEX","article_body":"Brii Biosciences Unveils BRiSC™, an siRNA Therapeutics Discovery Platform\nPR Newswire\n\nDURHAM, N.C. and BEIJING, Oct. 15, 2026\n\nProprietary BRiSC™ platform to advance the discovery and development of\nnext-generation dual-targeting siRNA medicines\n\nInitial focus on prevalent metabolic dysfunctions where complex disease\nbiology and overlapping comorbidities will benefit from coordinated modulation\nof multiple therapeutic targets\n\nDURHAM, N.C. and BEIJING, Oct. 15, 2026 /PRNewswire/ -- Brii Biosciences\nLimited (https://www.briibio.com/en/)  (\"Brii Bio\" or the \"Company\", stock\ncode: 2137.HK), a biotechnology company developing therapies to improve\npatient health and choice across diseases with high unmet medical need, today\nannounced the launch of BRiSC™ (Bispecific RNAiSilenCing), a proprietary\nsmall interfering ribonucleic acid (siRNA) therapeutics discovery platform to\nadvance the discovery and development of next-generation ribonucleic acid\n(RNA)-based therapies.\n\nBRiSC™ integrates a suite of four complementary technologies spanning\nsequence optimization, chemical modification, dual-targeting architectures,\nand targeted delivery approaches. Collectively, these complementary\ncapabilities are designed to enhance the selectivity, performance and\ntherapeutic reach of siRNA medicines, supporting the development of\ndifferentiated therapies for a broad range of diseases.\n\nThrough continued investment in its internal discovery organization,\nlaboratories in Beijing and Shanghai, and RNA technology capabilities, Brii\nBio has expanded its internal research and development capabilities across\ntarget discovery, translational science, and preclinical development. These\ncapabilities serve as the foundation for BRiSC™, which is already driving\nthe progression of multiple internal discovery programs.\n\nAs one of BRiSC™'s core capabilities, the dual-targeting architecture is\ndesigned to enable a single siRNA therapeutic to simultaneously silence two\ndistinct targets, addressing diseases driven by multiple biologic pathways,\nthrough a single treatment. Brii Bio is initially applying this approach to\nprevalent disease areas where complex biology and/or overlapping comorbidities\nmay potentially benefit from coordinated modulation of multiple therapeutic\ntargets.\n\n\"BRiSC™ reflects our commitment to building differentiated scientific\ncapabilities across multiple dimensions of siRNA therapeutic discovery and\ndevelopment,\" said Dr. Brian Johns, Chief Science Officer of Brii Bio. \"Our\ndual-targeting platform exemplifies this approach by combining innovative\nmolecular design with deep insights into disease biology to address conditions\ndriven by multiple unique pathways. Our goal is to develop differentiated RNA\ntherapeutics that can deliver broader and more meaningful benefits for\npatients\", he added.\n\nAbout Brii Bio\n\nBrii Biosciences Limited (\"Brii Bio\", stock code: 2137.HK) is a biotechnology\ncompany developing therapies to improve patient health by addressing diseases\nwith high unmet medical needs with limited treatment options. The Company is\nadvancing a broad pipeline of differentiated therapeutic candidates, including\ninternally discovered programs through its in-house RNA technology\ncapabilities such as its proprietary BRiSC™ siRNA discovery platform. The\nCompany is led by an experienced leadership team and has operations in China\nand the United States. For more information, visit www.briibio.com\n(https://www.briibio.com/) .\n\nView original\ncontent:https://www.prnewswire.com/news-releases/brii-biosciences-unveils-brisc-an-sirna-therapeutics-discovery-platform-302909942.html\n(https://www.prnewswire.com/news-releases/brii-biosciences-unveils-brisc-an-sirna-therapeutics-discovery-platform-302909942.html)\n\nSOURCE Brii Biosciences Limited\n\n\n\nMedia Inquiries: media@briibio.com; Investor Inquiries: ir@briibio.com; Partnering Inquiries: bd@briibio.com\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-10-15T11:30:01.319981565Z","server_sent_at_ms":1792063801319},"received_at":"2026-10-15T11:30:01.369Z","source_url":"https://www.prnewswire.com/news-releases/brii-biosciences-unveils-brisc-an-sirna-therapeutics-discovery-platform-302909942.html"},"analysis":null,"durationMs":null,"modelName":null}}